CHILDREN'S DIMETAPP NIGHTTIME COLD & CONGESTION OTC
Generic Name and Formulations:
Diphenhydramine HCl 6.25mg, phenylephrine HCl 2.5mg; per 5mL; syrup; grape-flavor; alcohol-free; contains sodium 4mg/5mL.
Pfizer Consumer Healthcare
Indications for CHILDREN'S DIMETAPP NIGHTTIME COLD & CONGESTION:
Nasal congestion, rhinorrhea, allergy symptoms.
20mL every 4 hours; max 6 doses/24 hours.
<6yrs: do not use. 6–11yrs: 10mL every 4 hours; max 6 doses/24 hours.
Children <6yrs old. During or within 14 days of MAOIs. Concomitant other diphenhydramine products (including topicals). For use as a sedative hypnotic.
Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Glaucoma. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
Antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Avoid alcohol. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children.
Syrup—4oz (w. dosing cup)
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds